Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued on Thursday. The firm set a “sell” rating on the stock.

Bio-Path Trading Up 11.9 %

NASDAQ:BPTH opened at $0.18 on Thursday. Bio-Path has a one year low of $0.12 and a one year high of $7.67. The company has a fifty day moving average price of $0.36 and a 200 day moving average price of $0.73.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.